John N. Bonfiglio, PhD joins Genprex’s Board of Directors with more than 30 years of pharmaceutical and biotechnology experience. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc. and most recently as President and COO of TapImmune, Inc., where he helped lay the groundwork for a successful merger with Marker Therapeutics, Inc. in October 2018 by uplifting TapImmune to Nasdaq and starting a robust clinical program in breast and ovarian cancers.
Dr. Bonfiglio began his career as a scientist with Allergan, Inc. before moving into project and business development. Over the course of his career he has held several executive leadership positions including President and CEO at Peregrine Pharmaceuticals, Inc., Executive Vice President and COO of Cypress Bioscience, Inc., President and CEO of The Immune Response Corporation and the President and CEO of Argos Therapeutics, Inc., among others. In those positions, he has succeeded in raising capital, lowering burn rates, setting corporate strategies, controlling corporate spending and managing clinical trials. Throughout his career he has helped raise more than $150 million in capital while helping companies relist and up list with national securities exchanges. Recently, he joined the Board of Directors of GT Biopharma, Inc., adding to his significant experience in the immuno-oncology field.